Makhdoom Sarwar: Advancing Liquid Biopsy Across Australia and New Zealand With Ngaio Diagnostics
Makhdoom Sarwar/ LinkedIn

Makhdoom Sarwar: Advancing Liquid Biopsy Across Australia and New Zealand With Ngaio Diagnostics

Makhdoom Sarwar, Co Founder and Chair / MOLAB at Molecular Oncology and Laboratory Medicine, shared on LinkedIn:

“A wonderful few days in Perth at the Thomas Ashworth CTC and Liquid Biopsy Conference, with some fascinating conversations on liquid biopsy, precision oncology and the future of cancer care. And, of course, a little time to enjoy the beautiful Swan River.

It was great to reconnect with colleagues and engage with the wider oncology community across Australasia and beyond. Some excellent discussions on the evolving role of liquid biopsy, especially its potential to contribute to better clinical decisions and more personalised cancer care.

Ngaio Diagnostics continues to support advances in liquid biopsy across Australia and New Zealand, working with clinical and scientific groups to explore its clinical applications across the region. It was also great to have our colleagues from CellBx Health join us from the UK, with several promising conversations around future collaborations.

Makhdoom Sarwar: Advancing Liquid Biopsy Across Australia and New Zealand With Ngaio Diagnostics

From Perth, a stopover in Sydney for a few more days of meetings and catching up with colleagues and friends. It was especially lovely to spend time with my dear friend Kevin, Prof of Medical Oncology at Liverpool Hospital, along with a few other colleagues. And Sydney never disappoints, especially when there is a little time to appreciate its beautiful harbour.

Almost time to head back to Christchurch, taking with me some wonderful memories, stimulating conversations and the pleasure of catching up with good friends and colleagues.”

You can also read:

Front Line Genomics Opens Registration for a Webinar Series on Liquid Biopsy and Cancer Diagnostics